Serum Institute of India: News
Trial will continue: Centre on SII vaccine's "adverse reaction" claims
With the coronavirus vaccine trials being conducted by Serum Institute of India (SII) being shrouded in controversy after a participant complained of an "adverse reaction," the Centre on Tuesday said there's no need to stop the process.
SII says Covishield 'safe' after trial participant sends legal notice
The Serum Institute of India (SII) on Tuesday said that its COVID-19 vaccine candidate was "safe and immunogenic," in response to allegations that a trial participant developed serious side-effects after being administered the dose.
SII to sue vaccine trial participant for Rs. 100 crore
The Serum Institute of India (SII) has said that it will seek Rs. 100 crore in damages from a COVID-19 vaccine trial participant for complaining about side-effects.
Applying for Covishield's emergency approval in 2 weeks: SII
The CEO of the Serum Institute of India (SII), Adar Poonawalla, on Saturday said that the company will seek the emergency-use authorization of the coronavirus vaccine 'Covishield' soon.
Modi embarks on 3-city tour to view COVID-19 vaccine development
Prime Minister Narendra Modi on Saturday embarked on a three-city tour to review the development of COVID-19 vaccines.
Manufacturing error in Oxford-AstraZeneca coronavirus vaccine raises pertinent questions
After announcing that their coronavirus vaccine candidate was nearly 70% effective, the University of Oxford and its partner, AstraZeneca, on Wednesday admitted to a manufacturing error, which has now sparked important questions about the results.
Can launch 100 million vaccine doses by January-February, says Poonawalla
The CEO of the Serum Institute of India (SII), Adar Poonawalla, has said that the institute can roll out 100 million doses of the COVID-19 vaccine by January-February.
Oxford vaccine to be available by April 2021 in India
Pune-based Serum Institute of India, which has partnered with Oxford University and British pharma giant AstraZeneca, plans to seek an emergency approval from the government of India next month, for providing the coronavirus vaccine to "corona warriors" and the elderly.
India to get 10cr COVID-19 vaccine doses by December: SII
The Serum Institute of India is hoping to produce 100 million (10 crore) doses of AstraZeneca and Oxford University's COVID-19 vaccine, CEO Adar Poonawalla said.
COVISHIELD vaccine could be realistic solution to COVID-19 pandemic: ICMR
The Indian Council of Medical Research (ICMR) and Pune-based Serum Institute of India (SII) on Thursday announced the completion of enrollment of participants to the Phase-3 clinical trials for the potential COVID-19 vaccine COVISHIELD in India.
Vaccine tracker: Covishield trials running smoothly; COVAXIN expected by February
Even as the COVID-19 outbreak has witnessed a downward trend in India, some states have been reporting large spikes in infections, indicating that the pandemic is far from over.
Affordable COVID-19 vaccine by January 2021, promises SII's Adar Poonawalla
Adar Poonawalla, the CEO of Serum Institute of India, said that the vaccine against coronavirus will be available in India by January 2021, two months from now, provided that the government gives approvals on time.
Vaccine tracker: Covishield expected by December; Moderna readies for launch
It has been almost a year since the coronavirus pandemic began, yet the virus is far from being brought under control.
Oxford's coronavirus vaccine could be available by December: Adar Poonawalla
In a welcome piece of development, Serum Institute of India's CEO Adar Poonawalla said on Wednesday that the coronavirus vaccine, being developed by Oxford University, could be available for use in India by December 2020.
India to play crucial role in COVID-19 vaccine process
As the world's largest vaccine manufacturer, India will play a major role in the vaccination efforts for COVID-19.
India may get COVID-19 vaccine by March 2021: SII official
India may get a vaccine for COVID-19 by March 2021, the Executive Director of the Serum Institute of India (SII) has said.
COVAXIN to Oxford: Coronavirus vaccine updates for India
Although the coronavirus outbreak in India has started to slow down, the country remains the second worst-hit in the world.
PM's vaccine arrangements will take care of all: Adar Poonawalla
As India's COVID-19 vaccine strategy becomes a point of debate, Adar Poonawalla has expressed confidence over Prime Minister Narendra Modi's vision to protect Indian citizens from the ongoing pandemic.
Vaccine expected by early 2021; nationwide immunization a challenge: Scientist
A vaccine for COVID-19 is likely to be ready by early 2021, a leading vaccine scientist has said. However, the real challenge for India would be conducting a vaccination drive for its population of 1.3 billion.
COVID-19 vaccine: Serum Institute to start final trials this week
As India's COVID-19 cases continue to surge by nearly a lakh every passing day, scientists are racing to get a vaccine ready as soon as possible.
After setback, Serum allowed to resume Oxford's coronavirus vaccine trial
Drugs Controller General of India (DCGI) Dr. VG Somani has permitted the Serum Institute of India (SII) to resume trial of the coronavirus vaccine candidate, being developed by the University of Oxford, revoking the last week's order that halted the process.
Coronavirus vaccine won't be available for all before 2024-end: Poonawalla
Adar Poonawalla, the CEO of the Serum Institute of India (SII), that has taken up the mammoth task of mass-producing the vaccine for novel coronavirus, asserted that the vaccine will not be available for the entire world before the end of 2024.
Coronavirus: Serum Institute ordered to halt recruitment for vaccine trial
The Drugs Controller General of India (DCGI) has ordered the Serum Institute of India (SII) to pause the recruitment of volunteers for Phase 2 and Phase 3 trials of the coronavirus vaccine, being developed by the University of Oxford and UK-pharma giant AstraZeneca.
Big setback: Serum pauses Oxford's coronavirus vaccine trial in India
A day after deciding to not halt the trial of the coronavirus vaccine, developed by the University of Oxford in collaboration with UK-pharma giant AstraZeneca, the Serum Institute of India (SII) on Thursday said it was also pausing the process.
Serum Institute gets notice after AstraZeneca halts coronavirus vaccine trial
Drug Controller General of India (DCGI) sent a notice to the Serum Institute of India (SII) asking why trials for the coronavirus vaccine candidate, developed by the University of Oxford, were not halted even when UK-based pharma giant AstraZeneca had stopped the process after a volunteer fell ill.
Bangladesh's Beximco enters COVID-19 vaccine deal with India's Serum Institute
One of Bangladesh's largest drugmakers, Beximco Pharmaceuticals, has announced that it will invest in the Serum Institute of India (SII) for the development of a coronavirus vaccine.
Coronavirus vaccine tracker: When will one be ready?
The global effort to develop a vaccine against the novel coronavirus SARS-CoV-2 continues as over 24 million people have been infected worldwide.
India: Serum Institute's COVID-19 vaccine goes into Phase-2/3 trials
In a major development, Adar Poonawalla's Serum Institute of India has started the Phase-2/3 trial of a promising COVID-19 vaccine licensed from AstraZeneca and Oxford University.
Indian government starts talks to procure COVID-19 vaccine: Details here
Amid surging COVID-19 cases and questions over the peak for India, the government has started working towards procuring a vaccine.
India likely to have COVID-19 vaccine by December: Adar Poonawalla
India should have a vaccine to exit the COVID-19 pandemic by the end of this year.
Serum Institute's COVID-19 vaccines will come at $3 per dose
In a major development, the Serum Institute of India has confirmed that the price of its foreign-licensed COVID-19 vaccines will be capped at $3 per dose in low-to-middle-income nations.
India's Serum Institute signs COVID-19 vaccine deal with America's Novavax
Serum Institute of India (SII) is set to source the COVID-19 vaccine developed by American biotech company Novavax.
SII gets nod for Oxford COVID vaccine phase 2/3 trials
The Serum Institute of India (SII) has gotten the approval to conduct phase 2 and 3 human clinical trials of the COVID-19 vaccine candidate developed by Oxford University.
Meet Adar Poonawalla, the man bringing COVID-19 vaccines to India
In the fight against COVID-19, or should we say the worst health crisis of our time, several institutes/organizations are racing to develop vaccines, anti-viral treatments.
Coronavirus vaccine will be available by 2021? Adar Poonawalla hopeful
Adar Poonawalla, the chief of Serum Institute of India (SII), is hoping that vaccine to fight coronavirus will be available in India by the first quarter of 2021.
India: Human trials of Oxford vaccine may start in August
The coronavirus vaccine, developed by researchers at Oxford University, could soon enter human trials phase in India, the CEO of Serum Institute of India informed on Monday.
COVID-19 vaccine: What are the latest updates?
With more than 5.3 lakh deaths and 1.14 crore infections, the COVID-19 pandemic continues to grow worse around the world.
COVID-19 vaccine: What are the latest updates?
With a sporadic increase in the number of cases and deaths, COVID-19 is growing beyond control in India.
India will start COVID-19 vaccine production next month: Details here
In a major development, Cyrus S. Poonawalla's Serum Institute of India has confirmed that it will start making a vaccine for COVID-19 next month.
Amid coronavirus crisis, this Indian business tycoon is growing richer
The outbreak of coronavirus, and the ongoing nation-wide lockdown to prevent it from growing worse, has disrupted businesses so much that their leaders and investors are bleeding money.